The nine-amino-acid peptide originally isolated from sleeping rabbits — studied for decades as a deep-sleep enhancer, though Western research has never fully embraced the claims.
DSIP (Delta Sleep-Inducing Peptide) is a 9 amino acid peptide first isolated from the cerebral venous blood of sleeping rabbits in 1974 by Monnier and colleagues. The name reflects its initial identification as something that induced delta-wave (slow-wave) sleep when injected into other rabbits.
Decades of subsequent research have been mixed. The peptide exists endogenously in humans, has measurable effects on stress and pain pathways, and has been studied in clinical trials for depression, chronic pain, and withdrawal syndromes. The consistent deep-sleep effect seen in early rabbit work has been harder to replicate in humans.
Not FDA approved. Not WADA prohibited. Research chemical with limited modern human trial data.
Crosses the blood-brain barrier and modulates several neurotransmitter systems including opioid, GABA, and serotonin pathways. Mechanism is multi-target rather than a single clean receptor interaction — which is partly why effects are inconsistent.
Reduces cortisol and ACTH release in response to stress in animal models. Also modulates pain signaling in opioid-adjacent ways, which is why it’s been studied for chronic pain and opioid withdrawal.
Plasma half-life is about 7 minutes — paradoxically short for a compound whose effects are reported to last overnight. One hypothesis: transient receptor activation triggers downstream cascades that outlast the peptide itself.
| Benefit | Evidence |
|---|---|
| Sleep quality | The one double-blind trial in insomniacs was negative. Bes 1992 (PMID 1299794) gave 16 chronic insomniacs IV DSIP at 25 nmol/kg or placebo across three lab nights. Sleep efficiency and sleep latency did improve — but the authors judged the significant effects "weak and in part could be due to an incidental change in the placebo group," no other measure moved including subjective sleep quality, and they concluded short-term DSIP for chronic insomnia "is not likely to be of major therapeutic benefit" |
| Stress / anxiety | Animal work is consistent — Khvatova 2003 (PMID 12668217) found DSIP protective for rat brain mitochondrial respiration under experimental hypoxia. No controlled human anti-stress trial exists |
| Chronic pain | A pilot study of seven patients (Larbig 1984, PMID 6548970) with migraine, vasomotor headache, tinnitus or psychogenic pain. Pain fell in 6 of 7 after IV dosing, with a parallel drop in depressive symptoms — but the comparison was baseline versus follow-up, with no placebo arm |
| Withdrawal syndromes | The largest DSIP dataset, and uncontrolled. Dick 1984 (PMID 6548969) gave IV DSIP to 107 inpatients in alcohol (47) or opiate (60) withdrawal, reporting symptoms resolved or markedly improved in 97% of opiate and 87% of alcohol patients. Read the design: no placebo, no blinding, outcomes judged by treating staff, and 13–22% of patients were excluded from evaluation. Anxiety was the slowest symptom to respond |
| Depression | Inconsistent; mixed Eastern European results |
Anecdotal reports in the peptide community commonly describe vivid dreams and improved subjective sleep quality but not the dramatic sleep induction the name implies.
The shape of the DSIP literature matters more than any single result. Almost all of it is from the 1980s, the sample sizes are small, and the studies that reported the most dramatic benefits — withdrawal, pain, the open insomnia series — had no placebo control. The one properly double-blinded trial in the population people buy DSIP for, chronic insomniacs, found effects its own authors called weak and possibly artefactual.
That is not a reason to dismiss it. The mechanism is real, it is endogenous, the safety record across four decades is genuinely clean, and the community reports of deeper sleep and vivid dreams are consistent. It is a reason to treat “delta sleep-inducing peptide” as a name given by 1970s rabbit researchers rather than a description of what it reliably does in humans.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNot medical advice. These figures describe what is reported in the literature and what practitioners and communities do — not a recommendation, and for most compounds here no human dose-finding study exists. Talk to a qualified healthcare provider.
The only published human dose in the available literature (PMID 6895513) used intravenous infusion at ~25 nmol/kg (roughly 1,500 mcg total for a 70 kg adult). SubQ and intranasal routes at 100–300 mcg are extrapolated from peptide-community practice — not established in controlled human trials. U-shaped dose-response has also been described (PMID 6145137), meaning higher doses can produce less effect, not more.
Most users treat DSIP as a PRN or short-cycle tool rather than continuous therapy. 10–14 day cycles followed by 2–4 week breaks. Long-term tolerance data in humans are limited — the absence of reported tolerance should not be interpreted as confirmed safety in extended use.
Not medical advice. These figures describe what is reported in the literature and what practitioners and communities do — not a recommendation, and for most compounds here no human dose-finding study exists. Talk to a qualified healthcare provider.
5 mg vial + 2 mL BAC water = 2500 mcg/mL
| Dose | Volume | Syringe Units |
|---|---|---|
| 100 mcg | 0.04 mL | 4 units |
| 200 mcg | 0.08 mL | 8 units |
| 300 mcg | 0.12 mL | 12 units |
Pre-filled with a typical DSIP (Delta Sleep-Inducing Peptide) setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
DSIP has an excellent reported safety profile. Decades of use in Eastern European clinical protocols have produced minimal adverse event reports.
DSIP (Delta Sleep-Inducing Peptide) is a research peptide not approved by the FDA for human use. It is sold only as a research chemical, and StackTrax does not endorse or facilitate personal use.
Quality varies enormously among research-chemical suppliers. At minimum, look for:
Lyvn does not carry DSIP (Delta Sleep-Inducing Peptide). They are the vendor we recommend elsewhere on this site, and they publish the full independent panel per batch — which makes their catalogue a useful yardstick for the criteria above even on a compound they do not stock. We are not recommending a specific supplier for DSIP (Delta Sleep-Inducing Peptide) itself, because we have no basis to.
For research use only. Not for human consumption. 21+.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNo. DSIP (Delta Sleep-Inducing Peptide) has never been FDA, EMA, or any other regulatory authority approved. The 1980s European academic literature (German-Swiss-Italian groups) explored DSIP in clinical research, but no pharmaceutical development pathway materialized. Vendor claims of "FDA review" for opioid withdrawal are not supported by any public docket and should be treated as marketing language. Sold in the US only as a research chemical.
Community-practice subcutaneous dosing is 100–300 mcg before bed, typically 30–60 minutes pre-sleep, often in 10–20 day cycles or PRN. Higher doses (250–500 mcg) are sometimes used for significant sleep issues. None of these come from FDA-approved labeling.
A typical reconstitution is 5 mg of DSIP + 2 mL of bacteriostatic water, yielding 2.5 mg/mL. A 200 mcg dose draws to 0.08 mL (8 units on a 100-unit insulin syringe), 300 mcg = 0.12 mL (12 units).
The mechanism is not fully established. DSIP crosses the blood-brain barrier (Banks 1982 PMID 6897451), suggesting central activity. The notable pharmacological feature is the mismatch between its plasma half-life (~7–15 minutes per Graf & Kastin 1984) and the much longer behavioural / EEG effects observed in studies — mechanism for the mismatch is unresolved (active metabolites? carrier-prolonged tissue exposure? downstream cascade?). It is NOT a sedative or GABAergic agent.
The 1980s European clinical literature reported subjective sleep improvement in some patient populations (insomnia, alcohol/opioid withdrawal, chronic pain) but trials were generally small and unblinded. The community use case for sleep is biologically plausible based on that literature but has not been confirmed in modern RCT-grade evidence. Reported effects in users vary widely — some report meaningful subjective improvement, others none.
Not specifically named on the WADA Prohibited List as of 2025–2026. WADA reserves discretion to sweep peptides under broad class language (S0 — Non-Approved Substances). Competitive athletes should verify the current-year list.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.